{
    "Trade/Device Name(s)": [
        "Snap-Top Split Key Cup for use with the GenPrime Drugs of Abuse Reader System"
    ],
    "Submitter Information": "GenPrime, Inc.",
    "510(k) Number": "K140665",
    "Predicate Device Reference 510(k) Number(s)": [
        "K080635"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIS",
        "JXM",
        "DIO"
    ],
    "Summary Letter Date": "December 2, 2014",
    "Summary Letter Received Date": "December 3, 2014",
    "Submission Date": "December 5, 2014",
    "Regulation Number(s)": [
        "21 CFR 862.3150",
        "21 CFR 862.3170",
        "21 CFR 862.3250"
    ],
    "Regulation Name(s)": [
        "Barbiturate test system",
        "Benzodiazepine test system",
        "Cocaine and cocaine metabolite test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamines (d-Amphetamine)",
        "Barbiturates (Secobarbital)",
        "Benzodiazepines (Oxazepam)",
        "Cocaine (Benzoylecgonine)",
        "Methamphetamine (d-Methamphetamine)",
        "Methadone (Methadone)",
        "Morphine",
        "Oxycodone",
        "Phencyclidine",
        "Marijuana (Delta-9-THC-COOH)"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Snap-Top Split Key Cup"
    ],
    "Instrument(s)/Platform(s)": [
        "GenPrime Drugs of Abuse (DOA) Reader System"
    ],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic lateral flow assay",
        "Competitive immunoassay",
        "Image analysis algorithm"
    ],
    "Methodologies": [
        "Lateral flow",
        "Competitive immunoassay"
    ],
    "Submission Type(s)": [
        "Test",
        "System",
        "Reader",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for the Snap-Top Split Key Cup used with the GenPrime Drugs of Abuse Reader System for qualitative detection of drugs of abuse in urine using lateral flow immunoassay.",
    "Indications for Use Summary": "For in vitro diagnostic prescription use in laboratories, point-of-care, and workplaces to qualitatively detect drug classes in human urine at specified cutoff concentrations with results requiring confirmation by more specific alternate chemical methods.",
    "fda_folder": "Toxicology"
}